Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

Inozyme Pharma, a clinical-stage rare disease biopharmaceutical company, has announced the dosing of the first infant with ENPP1 Deficiency in a Phase 1b trial of their drug, INZ-701. The trial, called ENERGY-1, aims to assess the safety and effectiveness of INZ-701 in infants with this condition. ENPP1 Deficiency is a progressive condition that can lead to severe symptoms and high mortality rat..